The Claim
The claim says that disease changes a person’s electromagnetic or energetic frequency pattern and that a bioresonance device can read those patterns, identify disease and sometimes feed corrected frequencies back to the body as treatment.
Products and clinics vary widely, so this investigation does not assume every machine makes identical claims. It evaluates the broad proposition that a clinically useful disease-specific frequency signal can be reliably detected and corrected by devices marketed as bioresonance.
Where It Comes From
Bioresonance developed from electrodermal testing traditions in which electrical measurements at the skin were interpreted as indicators of allergy, organ dysfunction or other disease. Later systems added digital signal processing, frequency libraries and therapeutic feedback.
The language now overlaps with real fields such as electrophysiology, biofeedback and electromagnetic medicine, which can make the distinction between established technologies and bioresonance claims difficult for consumers.
Why It Sounds Convincing
The body genuinely uses electrical signals. Electrocardiograms (ECGs) record cardiac electrical activity, electroencephalograms (EEGs) measure brain activity, nerve conduction can be tested and electromagnetic energy can be therapeutic in defined medical applications.
A device that produces graphs and numerical readings therefore looks scientifically plausible. The key question is whether the measured signal has been validated as a specific, reproducible marker of the disease the device claims to diagnose.
The Short Answer
Bioresonance has not been shown to be a reliable general diagnostic and treatment system.
Blinded studies of electrodermal allergy testing failed to distinguish allergic from non-allergic participants, and a randomized placebo-controlled trial found no added benefit for childhood atopic dermatitis.
Some small treatment studies—including a smoking-cessation pilot—have reported positive results. Those findings justify examining individual protocols but do not validate the broad theory that diseases have readable and correctable frequencies.
How It Would Have to Work
A diagnostic system needs a stable signal that differs between disease and non-disease, a defined measurement procedure, repeatability between operators and devices, and acceptable sensitivity and specificity against an independent reference standard.
A therapeutic system additionally needs evidence that the delivered signal changes a relevant biological process and improves clinical outcomes beyond placebo, expectation, regression to the mean and concurrent treatment.
What Actually Happens
Electrical properties of skin can vary with pressure, moisture, electrode contact, autonomic state and measurement setup. A device can therefore generate real electrical measurements without those measurements being disease-specific.
In established medical electrophysiology, signals are tied to known anatomy and validated against clinical outcomes. The problem with broad bioresonance is not that biology contains no electricity; it is that the proposed mapping from device reading to disease has not been reliably validated across the conditions claimed.
What the Evidence Shows
Double-blind studies of electrodermal testing in allergy found that the devices did not perform as claimed. A review of unproven allergy tests similarly found inadequate reproducibility and clinical validity.
Treatment evidence is more heterogeneous. A controlled atopic-dermatitis study was negative, while a 2014 sham-comparison smoking-cessation study reported higher quit rates with a MORA protocol. Although its abstract was indexed as randomized, the full article says participants were assigned alternately as they arrived, a predictable procedure rather than true random allocation. Other isolated studies have reported positive findings in selected conditions.
That pattern does not support a universal diagnostic-treatment mechanism. It supports evaluating each protocol independently and paying close attention to sample size, blinding, replication and prespecified outcomes.
The Strongest Evidence for the Claim
The strongest counter-evidence to a blanket dismissal is the existence of studies reporting positive outcomes, particularly the 2014 MORA smoking-cessation study. The authors enrolled 190 smokers, initially 95 per arm, and Table 3 reported 26 versus 15 abstinent participants at one year. Reported percentages were 28.6% versus 16.1%, but the percentages cannot be directly reconciled with the stated full-arm denominators. That difference warrants reporting, but the original methods assigned participants by alternation rather than genuine randomization, assessed quitting by telephone without biochemical verification, and declared that a coauthor consulted for the device manufacturer. Attrition and percentage denominators also require clarification. Independently replicated, well-randomized and objectively verified benefit could support a specific smoking-cessation intervention even before its mechanism was understood.
But a treatment effect in one condition would not automatically validate diagnostic scanning or a general theory of disease frequencies.
The Strongest Evidence Against It
The most direct evidence comes from blinded diagnostic tests. When operators and participants do not know the allergy status and the device cannot distinguish cases from controls, the claimed diagnostic signal fails a basic validation test.
Negative controlled treatment evidence also matters because many bioresonance sessions include strong contextual effects—attention, expectation and concurrent care—that uncontrolled testimonials cannot separate.
Common Viral Arguments
“Medicine already measures electrical signals, so bioresonance is scientifically established.”
Real electrophysiology does not validate every proposed electrical diagnostic. Each signal-to-disease relationship requires its own evidence.
“My scan identified foods that make me ill.”
A personally plausible result can occur without reliable diagnostic accuracy. Blinded reproducibility is the stronger test.
“There are randomized trials showing it works.”
Some small trials are positive. Their size, replication and disease-specific scope do not establish a universal frequency theory.
“Quantum physics proves everything has a frequency.”
Objects and biological processes can have frequencies, but that statement does not establish that a handheld device can infer a specific disease or correct it therapeutically.
The Reasoning Error
Misuse of scientific vocabulary gives terms such as frequency, resonance and energy more diagnostic meaning than has been demonstrated. False equivalence treats validated ECG/EEG or electromagnetic therapies as proof for bioresonance.
Cherry-picking can work in either direction: promoters may cite small positive trials while ignoring blinded diagnostic failures, while critics should not pretend positive trials do not exist.
What Would Change Our Conclusion?
For diagnosis, large preregistered blinded studies showing reproducible sensitivity and specificity against accepted reference tests would materially change the conclusion.
For treatment, independent randomized sham-controlled trials with clinically meaningful outcomes and protocol replication would be required. Mechanistic studies could then determine whether any benefit truly comes from the claimed frequency interaction.
Evidence Status
Status: Unsupported
Evidence quality: Moderate
Reliable general diagnostic performance has not been demonstrated, and treatment evidence is inconsistent and condition-specific. Positive small studies do not yet validate the broad body-frequency diagnosis-and-correction framework.
Sources
The evidence base includes both negative blinded diagnostic studies and a positive randomized treatment pilot. Because devices and protocols vary, evidence for one application should not be assumed to validate every product sold under the bioresonance label.
Corrections & Updates
October 9, 2026 — Factual correction and evidence clarification: the 2014 MORA smoking-cessation pilot was previously called randomized, but the full paper describes alternating assignments; its positive self-reported one-year result and inconsistent denominators remain reported with limitations (DOI 10.1159/000365742). Evidence Status unchanged.
Last Reviewed
October 9, 2026.